Increasing evidence suggests that treatment with IL-1 inhibition/neutralization will extend to diseases outside the rheumatologic scope and will include the treatment of more common diseases such as coronary heart diseases, i.e., myocardial infarction, and especially acute heart failure. Here, IL1B is linked to myocardial infarction.